Endocrinology
2 drugs are in development for Diabetes Mellitus, Type 2.
- Companies
- 2
- Clinical trials
- 128
Prepared research question
Which programs lead the Diabetes Mellitus, Type 2 pipeline—and what evidence could change the picture?
Traceable citations · Unknowns marked
Drug Pipeline by Phase
| Drug | Company |
|---|---|
| rybelsus | Novo Nordisk A/S (NVO) |
| Drug | Company |
|---|---|
| Tirzepatide | ELI LILLY & Co (LLY) |
About this indication
Diabetes Mellitus, Type 2 context
Also known as: Adult-Onset Diabetes Mellitus, Diabetes Mellitus, Ketosis Resistant, Diabetes Mellitus, Maturity Onset, Diabetes Mellitus, Slow Onset, Diabetes Mellitus, Type II, Diabetes, Maturity-Onset, Diabetes, Type 2, MODY (Maturity-onset diabetes of the young), NIDDM, Non-Insulin-Dependent Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Stable Diabetes Mellitus
Prevalence
7269.6 / 100K
Incidence
321.8 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Diabetes Mellitus, Type 2?
BioSniper tracks 2 drugs in development for Diabetes Mellitus, Type 2 across 2 companies.
How many clinical trials target Diabetes Mellitus, Type 2?
There are 128 clinical trials targeting Diabetes Mellitus, Type 2 tracked by BioSniper.
What is the prevalence of Diabetes Mellitus, Type 2?
The estimated prevalence of Diabetes Mellitus, Type 2 is approximately 7269.6 per 100,000 population.